- Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
- Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
- Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
- Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
- Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
- Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
- Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
- Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
- Enlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19
More ▼
Key statistics
As of last trade, Enlivex Therapeutics Ltd (ENLV:NAQ) traded at 1.34, 16.52% above the 52 week low of 1.15 set on Apr 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.30 |
---|---|
High | 1.37 |
Low | 1.30 |
Bid | 1.34 |
Offer | 1.37 |
Previous close | 1.27 |
Average volume | 647.53k |
---|---|
Shares outstanding | 18.60m |
Free float | 14.98m |
P/E (TTM) | -- |
Market cap | 23.62m USD |
EPS (TTM) | -1.56 USD |
Data delayed at least 15 minutes, as of Apr 23 2024 15:57 BST.
More ▼